The Covid-19 vaccine candidates by University of Oxford-AstraZeneca, Moderna Inc, Pfizer Inc-BioNTech and Chinese firm Sinovac & Sinopharm are all undergoing Phase III trials at present.

Oxford-AstraZeneca coronavirus vaccine price:

Adar Poonawalla, CEO of Serum Institute of India, said the cost of the vaccine is estimated to be below ($13) and will be called Covishield in India. In the UK, Oxford has said the vaccine will be available at a low cost.

Moderna vaccine price:

Moderna prices COVID-19 vaccine at $32-$37 per dose for smaller volume deals. Moderna Inc, which is working on launching their prototype, mRNA-1273 in the coming months recently announced that they will be offering their vaccine to the public, costing between $32-$37.

Moderna's two-dose vaccine regimen would cost between $64 and $74 per person

Pfizer-BioNTech coronavirus vaccine price:

In The Netherlands, Germany, France and Italy, the vaccine will be priced at $3-4 per dose, as mentioned in Financial Times. In the US, the price will be $39 for what is likely to be a two-dose course of treatment, or $19.50 per dose.

Pfizer, which has already signed pacts with the US government also announced that they will be capping the price of their product under $20 and will make it available for the public.

The U.S. government agreed to purchase 100 million doses of the Pfizer/BioNTech vaccine at a price that amounts to $39 for what is likely to be a two-dose course of treatment, or $19.50 per dose.

Sinopharm coronavirus vaccine price:

Sinopharm chief says COVID-19 vaccine will cost less than $145 for 2-dose regimen. People must pay the full price for most other vaccines, because they’re not included in the national insurance scheme. At $145 for a two-dose regimen.

GAVI vaccine alliance

The GAVI vaccine alliance, of which India is a part and has pledged $15 million, said it would seek to negotiate tiered pricing for richer and poorer countries. Seth Berkley, chief executive of the alliance, which is co-leading the COVAX facility, told Reuters that it was targeting a $40 price for the vaccines in the wealthy countries.

With over 75 countries expressing interest in joining COVAX, the alliance aims to secure supplies of and deliver 2 billion doses across countries who sign up by the end of 2021.

U.S. sets global benchmark for COVID-19 vaccine price at around the cost of a flu shot

The deal, which is contingent on an approvable product, secures enough vaccine to inoculate 50 million Americans for about $40 a person, or about the cost of annual flu shots, and is the first to provide a direct window into likely pricing of successful COVID-19 vaccines.

While Pfizer, Moderna and Merck & Co have said they plan to sell their vaccines at a profit, some drug makers, including Johnson & Johnson have announced plans to price their vaccines on a not-for-profit basis. Johnson and Johnson has said it would make the Covid-19 vaccine available at $10 for “emergency pandemic use”.

Source:

https://indianexpress.com/article/explained/what-we-know-of-coronavirus-covid-19-vaccine-pricing-oxford-covishield-covaxin-moderna-6529371/

https://www.npr.org/sections/health-shots/2020/08/06/899869278/ 

https://www.reuters.com/article/us-health-coronavirus-vaccine-pricing-an/u-s-sets-global-benchmark-for-covid-19-vaccine-price-at-around-the-cost-of-a-flu-shot-idUSKCN24O1DA  

https://www.fiercepharma.com/vaccines/china-sinopharm-chief-narrows-down-covid-19-vaccine-price-to-within-145-for-2-dose-regimen